Open-Label Phase 3 Clinical Study to Investigate Safety and Immunogenicity of a Single VLA2001 Booster Vaccination in Volunteers Aged ≥18 Years, After Priming With Another Inactivated COVID-19 Vaccine
Latest Information Update: 14 Feb 2023
At a glance
- Drugs VLA 2001 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 07 Feb 2023 Status changed from not yet recruiting to withdrawn prior to enrolment, because funding was suspended.
- 21 Sep 2022 New trial record